Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Rare Diseases

Lung Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Sarcoma

Breast Diseases

Skin Diseases

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Soft Tissue Sarcoma

All Drugs and Chemicals

Antibodies

Hormones

Immunoglobulins

Hormone Antagonists

IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year

figitumumab

growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year

pegvisomant

Pfizer CT.gov Call Center

This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.

This study was closed to enrollment on 18 April 2011 due to inability to recruit patients on a timely basis as well as business reasons. Study closure was not related to any safety concerns.

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors

Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. AEs were graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 (Grade \[Gr\] 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death). Relatedness to \[study drug\] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

DLT was defined as any of the following events occurring during DLT period and considered related to study medication: Grade (Gr) 4 neutropenia lasting \>=7 days, febrile neutropenia (Gr 3 or 4 neutropenia, fever \>=38.5 degrees Celsius, lasting over 24 hours), neutropenic infection (Gr \>=3 neutropenia, infection); Gr 3 or 4 thrombocytopenia associated with bleeding or Gr 4 thrombocytopenia \>=7 days; Gr 3 or 4 lymphopeniab accompanied by an opportunistic infection; other non-hematologic Grade 4 toxicities or symptomatic Gr 3 toxicities that require medical intervention and 14 days to resolve.

The effect of the combined therapy with figitumumab and pegvisomant on circulating concentrations of total IGF-1 was assessed.

Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab from Cycle 2 to the end of treatment.

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) of figitumumab in cycle 1.

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)of figitumumab after Cycle 1

The trough concentration-time profile (AUCtrough) of pegvisomant was to be analyzed by noncompartmental methods.

The effect of combining figitumumab with pegvisomant was analyzed to assess whether pegvisomant reverses figitumumab-induced glucose intolerance at various pegvisomant dose levels. The change in glucose load was assessed by Glucose Tolerance Testing (GTT) at baseline (fasting), during Cycle 1 following administration of figitumumab alone (post load), and near the end of Cycle 2 (post load) following combined therapy with figitumumab and pegvisomant.

Percentage of participants with positive total or neutralizing ADA for figitumumab.

Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST)version 1.1. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as ≥30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST version 1.1. Confirmed responses are those that persist on repeat imaging study ≥4 weeks after initial documentation of response.

Pfizer

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Figitumumab 20 milligram/kilogram (mg/kg) intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 10 mg subcutaneously once daily up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days.

Figitumumab 20 mg/kg + Pegvisomant 10 mg

Figitumumab 20 milligram/kilogram (mg/kg) intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles (up to total duration of 27 cycles). Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 20 mg subcutaneously once daily up to total duration of 27 cycles. Each cycle was of 21 days.

Figitumumab 20 mg/kg + Pegvisomant 20 mg

Figitumumab 20 milligram/kilogram (mg/kg) intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 10 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days.

Figitumumab 20 mg/kg +Pegvisomant 10 mg

Figitumumab 20 milligram/kilogram (mg/kg) intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 20 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days.

Total

Age Continuous

Sex: Female, Male

The study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

Pfizer ClinicalTrials.gov Call Center

Number of participants with AEs

Number of participants with SAEs

Number of participants with Gr 3 or Gr 4 AEs

Number of participants with Gr 5 AEs

Figitumumab 20mg/kg + Pegvisomant 10 mg

Figitumumab 20 milligram/kilogram (mg/kg) intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 20 mg subcutaneously once daily up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days.

Figitumumab 20mg/kg + Pegvisomant 20 mg

Safety analysis set: all enrolled participants who received at least 1 dose of either of the study medications.

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Safety analysis set: all enrolled participants who received at least 1 dose of either of the study medications. N=number of participants remained on treatment throughout the required DLT period and included as analyzed for DLT based on the defined DLT evaluability specifications.

Number of Participants With Dose Limiting Toxicities (DLT)

Baseline/Cycle 1 (n = 16, 6)

Cycle 2 (n = 12, 6)

Cycle 3 (n = 6, 5)

Cycle 4 (n = 5, 3)

Cycle 5 (n = 3, 4)

Cycle 6 (n = 2, 2)

Cycle 7 (n = 1, 2)

Cycle 8 (n = 0, 2)

Cycle 9 (n = 0, 2)

Cycle 10 (n = 0, 2)

Cycle 11 (n = 0, 2)

Cycle 12 (n = 0, 2)

Cycle 13 (n = 0, 2)

Cycle 14 (n = 0, 2)

Cycle 15 (n = 0, 2)

Cycle 16 (n = 0, 2)

Cycle 17 (n = 0, 2)

Cycle 18 (n = 0, 2)

Cycle 19 (n = 0, 1)

Cycle 20 (n = 0, 2)

Cycle 21 (n = 0, 2)

Cycle 22 (n = 0, 1)

Cycle 23 (n = 0, 1)

Cycle 24 (n = 0, 1)

Cycle 25 (n = 0, 1)

Cycle 26 (n = 0, 1)

Cycle 27 (n = 0, 0)

Follow-Up (n = 2, 1)

Biomarker analysis set: all enrolled participants who had at least 1 baseline or on-study sample submitted. N=number of participants who were evaluable for IGF-1 Levels at prespecified time points.

Serum Circulating Insulin-like Growth Factor (IGF-1) Levels

PK samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

Cycle 1: Maximum Observed Plasma Concentration (Cmax) of Figitumumab

Maximum Observed Plasma Concentration (Cmax) of Figitumumab

Cycle 1: Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab

Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab

Cycle 1: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Figitumumab

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)of Figitumumab

Area Under the Trough Concentrations (AUCtrough)

Screening (n = 17, 6)

Cycle 1 Day 8 (n = 15, 5)

Cycle 2 Day 15 (n = 4, 5)

Glucose tolerance set: All enrolled participants who started treatment and who had at least one baseline or on-study sample submitted. N=number of participants with analyable data for this outcome measure.

Mean Change in Glucose Levels Between Fasting and Post Glucose Load

ADA samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

Percentage of Participants Reporting Positive Anti-Drug Antibodies (ADA) Response for Figitumumab

Response-evaluable set: All participants who started Cycle 1 with an adequate baseline tumor assessment and at least 1 follow up tumor assessment.

Number of Participants With Objective Response

Overall Study

Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

Hypoglycemic Agents

Amino Acids

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Antibodies, Monoclonal

Insulin

Insulin, Globin Zinc

Erlotinib Hydrochloride

Tubulin Modulators

Antimitotic Agents

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunologic Factors

Tyrosine

1. Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin
2. Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib

Phase 2 Arm A:

CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles

CP-751,871

Phase 2 Arm A:

Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles

Phase 2 Arm B:

Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles

paclitaxel

Phase 2 Arm A:

Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles

Phase 2 Arm B:

Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles

carboplatin

Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)

Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)

Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)

Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)

erlotinib

Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib.

Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

A Phase 1b Dose Escalation/Phase 2 Randomized, Non-Comparative, Multiple Center, Open Label Study Of CP 751,871 In Combination With Paclitaxel And Carboplatin And Of Paclitaxel And Carboplatin Alone As First Line Treatment For Advanced Non-Small Cell Lung Cancer

The maximum tolerated dose of CP-751,871 in combination with paclitaxel and carboplatin is the highest dose level below the Maximum Administered Dose (the dose level at which 2 or more out of 3 to 6 patients experience a Dose Limiting Toxicity at a dose level in Cycle 1) at which none or one out of 6 patients experience a Cycle 1 Dose Limiting Toxicity.

Percentage of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as ≥30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study ≥4 weeks after initial documentation of response.

HAHA are indicators of immunogenicity to CP-751,871.

Blood samples were collected to enumerate the number of total CTCs and CTC insulin-like growth factor 1 receptor (IGF-IR) expression

AUC (0-504)= Area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the 21-day cycle, 504 hours(0-504)

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) extrapolated to infinite time.

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Accumulation ratio (Cycle 4 AUC504 / Cycle 1 AUC504) (Rac)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

HAHA are indicators of immunogenicity to CP-751,871

The MDASI is a 19-item questionnaire that assesses the severity of 13 symptoms over the past 24 hours, as well as how much the symptoms interfered with 6 areas of function (eg, walking, work, mood), when the symptom was "at its worst". Each item is scored from 0 to 10, with '0' indicating that the symptom was either not present or did not interfere with their activities, and '10' indicating that the symptom was "as bad as you can imagine" or "interfered completely" with their life. Total average score range: 0 to 10.

The QLQ-C30/-LC13 is a 43 item, self-administered questionnaire designed to assess health outcomes in clinical trials. In addition to global quality of life, the measure assesses 5 functional domains (physical, role, cognitive, emotional and social functioning) and specific symptoms (eg, nausea, pain). Each item is rated on a 1-4 scale with '1' representing "not at all" and '4' "very much". Within domains, items are scored to obtain a total score with higher scores representative of poorer HRQoL. Scale score range: 0 to 100.

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause whichever comes first. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).

Time in months from start of study treatment to first documentation of objective tumor progression. TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).

Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.44. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Single intravenous (IV) dose of CP-751,871 0.05 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 0.05 mg/kg + Paclitaxel + Carboplatin (Phase 1b)

Single intravenous (IV) dose of CP-751,871 0.1 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 0.1 mg/kg + Paclitaxel + Carboplatin (Phase 1b)

Single intravenous (IV) dose of CP-751,871 0.8 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 0.8 mg/kg + Paclitaxel + Carboplatin (Phase 1b)

Single intravenous (IV) dose of CP-751,871 1.5 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 1.5 mg/kg + Paclitaxel + Carboplatin (Phase 1b)

Single intravenous (IV) dose of CP-751,871 3 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 3 mg/kg + Paclitaxel + Carboplatin (Phase 1b)

Single intravenous (IV) dose of CP-751,871 6 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 6 mg/kg + Paclitaxel + Carboplatin (Phase 1b)

Single intravenous (IV) dose of CP-751,871 10 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 10 mg/kg + Paclitaxel + Carboplatin (Phase 1b)

Single intravenous (IV) dose of CP-751,871 20 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 20 mg/kg + Paclitaxel + Carboplatin (Phase 1b)

Single intravenous (IV) dose of CP-751,871 20 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each cycle (up to 1 year). Erlotinib 150 mg/day orally on Cycle 1 Day 1 (up to 1 year). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at a dose to attain the target area under the concentration-time curve (AUC) of 6 milligram/milliliter\*minute (mg/mL\*min), IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

CP-751,871 + Paclitaxel + Carboplatin + Erlotinib (Phase 1b)

Single intravenous (IV) dose of CP-751,871 10 or 20 milligram/kilogram (mg/kg) over 2.5 hours on Day 1 of each Cycle (up to 17 cycles). Paclitaxel 200 mg/square meter (m\^2), IV over 3 hours on Day 1 of each cycle (up to 6 cycles) followed by carboplatin at dose to attain target area under the concentration-time curve (AUC) of 6 mg/mL\*min, IV over 15-60 minutes on Day 1 of each cycle (up to 6 cycles). Each cycle was 21 days cycle.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors	NCT00976508	Colorectal Neop... Lung Neoplasms Breast Neoplasm... Prostatic Neopl... Sarcoma	figitumumab pegvisomant	10 Years -	Pfizer
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer	NCT00147537	Carcinoma, Non-...	CP-751,871 paclitaxel carboplatin CP-751,871 paclitaxel carboplatin erlotinib	18 Years -	Pfizer
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer	NCT00977561	Small Cell Lung...	figitumumab Cisplatin (Or C... Etoposide Cisplatin (Or C... Etoposide	18 Years -	Pfizer
CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery	NCT00635245	Breast Cancer	figitumumab imaging biomark... laboratory biom... pharmacological... conventional su... magnetic resona... neoadjuvant the...	18 Years -	Pfizer
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer	NCT00673049	Carcinoma, Larg... Carcinoma, Non-... Carcinoma, Squa... Carcinoma, Aden...	CP 751,871 (Fig... Erlotinib Erlotinib	18 Years -	Pfizer
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer	NCT00673049	Carcinoma, Larg... Carcinoma, Non-... Carcinoma, Squa... Carcinoma, Aden...	CP 751,871 (Fig... Erlotinib Erlotinib	18 Years -	Pfizer
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer	NCT00977561	Small Cell Lung...	figitumumab Cisplatin (Or C... Etoposide Cisplatin (Or C... Etoposide	18 Years -	Pfizer
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer	NCT00147537	Carcinoma, Non-...	CP-751,871 paclitaxel carboplatin CP-751,871 paclitaxel carboplatin erlotinib	18 Years -	Pfizer

Spots Global Cancer Trial Database for figitumumab

Every month we try and update this database with for figitumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for figitumumab

Every month we try and update this database with for figitumumab cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for figitumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.